In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors.

Kidney and nerve tissue cells can form memories much like brain cells, one new study has found. Another recent study says ...

Hims & Hers' robust Q3 2024 performance, driven by a 44% increase in subscribers and 77% y/y revenue growth, underscores its ...

Indian pharmaceutical sector faces new challenges in 2025, from UCPMP implementation to global dynamics and opportunities in ...

Generic drugs are incredibly important in the ... such as GLP-1 analogues like liraglutide or semaglutide. Originally, liraglutide and semaglutide are produced at an industrial scale using ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

I found that so many people were making their own GLP-1s and taking smaller amounts than normally prescribed,” she said. “I ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...

In a world grappling with obesity and chronic disease, GLP-1 drugs like Ozempic are emerging as transformative game-changers.

(In 2024 research published in the Journal of the American Medical Association, participants who took tirzepatide for weight loss generally saw greater benefit from tirzepatide, compared to ...